Trials / Completed
CompletedNCT00003657
High-dose ICE With Amifostine
High Dose Ifosfamide, Carboplatin and Etoposide With Amifostine Chemoprotection
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Dana-Farber Cancer Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the combination of amifostine and high dose chemotherapy with blood stem cell support. Amifostine is a druf developed to protect normal tissues against the toxicities of chemotherapy and radiotherapy and has reduced the side effects of chemotherapy given at conventional doses.
Conditions
- Bladder Cancer
- Brain and Central Nervous System Tumors
- Carcinoma of Unknown Primary
- Extragonadal Germ Cell Tumor
- Head and Neck Cancer
- Kidney Cancer
- Lung Cancer
- Ovarian Cancer
- Sarcoma
- Testicular Germ Cell Tumor
- Unspecified Adult Solid Tumor, Protocol Specific
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | filgrastim | |
| DRUG | Amifostine | |
| DRUG | Carboplatin | |
| DRUG | Etoposide | |
| DRUG | Ifosfamide | |
| PROCEDURE | peripheral blood stem cell transplantation |
Timeline
- Start date
- 1998-07-01
- Primary completion
- 2000-11-01
- Completion
- 2002-06-01
- First posted
- 2004-03-31
- Last updated
- 2017-01-20
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00003657. Inclusion in this directory is not an endorsement.